Vogenx, Inc.
VOGX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for VOGX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VOGX
Vogenx, Inc. (VOGX) is an early-stage biopharmaceutical company focused on developing mizagliflozin, a selective SGLT1 inhibitor, for disorders related to glucose absorption and postprandial dysregulation, including post-bariatric hypoglycemia (PBH), gastroparesis, and GIP-dependent Cushing's syndrome. The company has no approved products and has not generated any revenue from product sales.
Key risk: Clinical development delays
Tracking 2 clinical trials · 1 catalyst for Vogenx, Inc..
Vogenx, Inc. (VOGX) is an early-stage biopharmaceutical company focused on developing mizagliflozin, a selective SGLT1 inhibitor, for disorders related to glucose absorption and postprandial dysregulation, including post-bariatric hypoglycemia (PBH), gastroparesis, and GIP-dependent Cushing's syndrome. The company has no approved products and has not generated any revenue from product sales.
- Vogenx is advancing mizagliflozin, a selective SGLT1 inhibitor, for PBH, gastroparesis, and GIP-dependent Cushing's syndrome [sec · filed 2026-07-15].
- The company has an accumulated deficit of $11.3 million as of March 31, 2026 [sec · filed 2026-07-15].
- Vogenx has not completed any clinical trials beyond Phase 2 and has no products approved for sale [sec · filed 2026-07-15].
- The company plans to initiate a Phase 2B randomized, placebo-controlled, double-blind, repeat dose parallel study in participants with PBH starting 2026-10-01 [upcoming catalysts].
- Vogenx is also developing VGX-2857 for weight maintenance and aims to build a fully integrated biopharmaceutical company [sec · filed 2026-07-15].
What works
- Mizagliflozin targets established endpoints for regulatory approval in areas with significant unmet medical needs, such as PBH and gastroparesis [sec · filed 2026-07-15].
- The company has a clear pipeline strategy including mizagliflozin and VGX-2857, with plans to expand through internal discovery and strategic collaborations [sec · filed 2026-07-15].
- Vogenx is structured as a smaller reporting company, which may allow for reduced disclosure requirements and lower compliance costs [sec · filed 2026-07-15].
What to weigh
- Vogenx is an early-stage company with a limited operating history, having commenced operations in February 2021, and has not yet demonstrated the ability to complete large-scale pivotal trials or obtain regulatory approvals [sec · filed 2026-07-15].
- The company has an accumulated deficit of $11.3 million as of March 31, 2026, and expects operating losses to increase substantially as it advances its pipeline [sec · filed 2026-07-15].
- Vogenx has no approved products and has not generated any revenue from product sales, making it entirely dependent on successful development and commercialization of its candidates [sec · filed 2026-07-15].
- The actual patient populations for the diseases targeted may be smaller than anticipated, which could hinder clinical trial enrollment and market potential [sec · filed 2026-07-15].
From the filings
Quoted directly from source documents.
Vogenx is developing mizagliflozin for PBH, gastroparesis, and GIP-dependent Cushing's syndrome.
“advance the development of our mizagliflozin product candidates for the treatment of PBH, Gastroparesis, and GIP-dependent Cushing's Syndrome”
SEC filings · July 15, 2026
Vogenx has an accumulated deficit of $11.3 million as of March 31, 2026.
“We had an accumulated deficit of $10.8 million and $11.3 million as of December 31, 2025 and March 31, 2026, respectively.”
SEC filings · July 15, 2026
Vogenx has not completed any clinical trials beyond Phase 2.
“We are an early-stage company with a limited operating history, have not completed any clinical trials beyond Phase 2 and have no products approved for sale.”
SEC filings · July 15, 2026
Catalyst timeline
- 2026-10-01 · Phase2_Start · post-bariatric — Phase 2 Start: Phase 2B Randomized, Placebo-Controlled, Double-Blind, Repeat Dose Parallel Study in Participants Wi — Initiation of a Phase 2B study for mizagliflozin in post-bariatric hypoglycemia, a key clinical milestone for the company.
Risks & what to watch (4)›
Key risks
- Clinical development delays — Potential delays or failures in clinical trials due to insufficient financial resources, regulatory issues, or manufacturing challenges [sec · filed 2026-07-15].
- No revenue or approved products — Vogenx has no approved products and no revenue from product sales, relying entirely on future development success [sec · filed 2026-07-15].
- Smaller patient populations — Actual number of patients for targeted diseases may be smaller than estimated, affecting enrollment and market size [sec · filed 2026-07-15].
- Dependence on mizagliflozin — Business is highly dependent on the success of mizagliflozin; any issues could materially harm development plans [sec · filed 2026-07-15].
What to watch
- Initiation of Phase 2B study for mizagliflozin in PBH starting 2026-10-01 [upcoming catalysts].
- Progress of VGX-2857 development for weight maintenance [sec · filed 2026-07-15].
- Ability to raise additional capital to fund operations and clinical trials [sec · filed 2026-07-15].
- Regulatory interactions and potential approvals for mizagliflozin [sec · filed 2026-07-15].
Sources: SEC filings · Generated August 28, 2026 · How we verify sources →
Run Vogenx, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Vogenx, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Catalysts
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for Vogenx, Inc.?
Vogenx, Inc. (VOGX) is an early-stage biopharmaceutical company focused on developing mizagliflozin, a selective SGLT1 inhibitor, for disorders related to glucose absorption and postprandial dysregulation, including post-bariatric hypoglycemia (PBH), gastroparesis, and GIP-dependent Cushing's syndrome. The company has no approved products and has not generated any revenue from product sales.
What is Vogenx, Inc.'s next catalyst?
Vogenx, Inc.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: Phase 2B Randomized, Placebo-Controlled, Double-Blind, Repeat Dose Parallel Study in Participants Wi" — expected October 1, 2026.
Who is the CEO of Vogenx, Inc.?
Mr. James Green is the chief executive officer of Vogenx, Inc. (VOGX).
Where is Vogenx, Inc. headquartered?
Vogenx, Inc. (VOGX) is headquartered in Raleigh, NC, United States.
What therapeutic areas does Vogenx, Inc. focus on?
Vogenx, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.